Key result
A systematic review of 26 studies found no reported evidence of non-haemorrhagic adverse events occurring as a result of drug-drug interactions with flurbiprofen 8.75 mg.
Why the study?
Flurbiprofen adverse events can increase with concomitant medications, but evidence on non-haemorrhagic adverse events from drug-drug interactions with the 8.75 mg dose needed collation.
Does flurbiprofen 8.75 mg used concomitantly with other medications increase the risk of non-haemorrhagic adverse events?
Systematic Review
Does flurbiprofen 8.75 mg used concomitantly with other medications increase the risk of non-haemorrhagic adverse events?
A systematic review found no reported cases of non-haemorrhagic adverse events resulting from drug-drug interactions with flurbiprofen 8.75 mg in clinical trials, highlighting the need for real-world observational studies.
Supports concomitant use without non-haemorrhagic DDI concerns in trials; leaves open real-world risks requiring observational studies.
Background: Flurbiprofen 8.75 mg lozenges and oromucosal sprays are used for symptomatic relief of sore throat in patients aged 12 years and over. The documented adverse events of flurbiprofen use include those related to its pharmacological actions, namely, increased risk of haemorrhagic events, however other adverse events (such as nephrotoxicity and cardiac failure) have been known to occur. The likelihood of occurrence of adverse events increases when flurbiprofen is used concomitantly with some other medications. Therefore, the objective of this systematic review was to collate the current evidence on adverse events which occur with flurbiprofen 8.75 mg dose (any formulation), in particular as a result of interaction with other medicinal products, with a focus on non-haemorrhagic events. Methods: Systematic searches of the literature were conducted to identify literature on any formulation of flurbiprofen 8.75 mg up to the date of the electronic database search (data lock: 28 April 2020). Publications were screened to identify studies reporting non-haemorrhagic adverse events with flurbiprofen 8.75 mg and/or non-haemorrhagic adverse events in the comparator arm. Data extraction was performed for eligible studies according to pre-defined criteria and summarised in narratives, tables and figures. Risk of bias and certainty of evidence assessments were planned for each included study where results relating to the primary objective of the systematic review were available. Results: Of 1,528 publications identified by systematic literature searches, 26 met the inclusion criteria and were included in this review. None of these 26 studies contained information on non-haemorrhagic adverse events occurring as a result of a drug-drug interaction (interaction with concomitant medication used with flurbiprofen 8.75 mg), as per the primary objective and secondary objectives of the systematic review. Conclusion: Results from this systematic review on the risk of non-haemorrhagic events did not provide evidence for these events occurring as a result of interaction with other medicinal products. Additional appropriately designed studies would be required to confirm whether these findings suggest a true absence of risk or limitations in reporting.
No takes yet. Share an insight, caveat, or question.
Evans et al. (2024) conducted a systematic review in Sore throat. Flurbiprofen with concomitant medications vs. Placebo or active comparator was evaluated on Frequency of all non-haemorrhagic adverse events occurring as a result of concomitant use of flurbiprofen 8.75 mg dose with other medicinal products (drug-drug interactions). A systematic review of 26 studies found no reported evidence of non-haemorrhagic adverse events occurring as a result of drug-drug interactions with flurbiprofen 8.75 mg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: